The development of high-throughput technologies able to simultaneously investigate thousands of genes (e.g. single nucleotide polymorphism-array, gene expression microarray, etc.) has opened a new era in translational research. Obtaining a molecular classification of hepatocellular carcinoma, however, remains a striking challenge. This review summarizes the molecular classifications of hepatocellular carcinoma reported so far, analyzes the status of targeted therapies tested in clinical trials, and evaluates feasibility of personalized medicine approaches in hepatocellular carcinoma. Recent findings Different investigators attempted to classify patients according to their liver cancer molecular background, a feature that will path the way for trial enrichment and personalized medicine. Currently, hepatocellular carcinoma can be classified in molecular classes according to Wnt-b-catenin pathway activation, proliferation signature activation (associated with chromosomal instability), and other subgroups. In parallel, the first-time-ever positive results of a phase III trial in advanced hepatocellular carcinoma with the multikinase inhibitor sorafenib have encouraged this approach. Summary Selection of patient candidates according to their tumor molecular background is a reality in human malignancies. Thus, a molecular classification is essential to allow the development of new targets, and to customize therapies in patients with hepatocellular carcinoma.
Introduction
Hepatocellular carcinoma (HCC) is the leading cause of death among cirrhotic patients [1] . On the basis of recent estimations, close to 625 000 new cases of HCC will be diagnosed worldwide every year. HCC mortality ranks third among all cancers, only behind lung and colon cancer [2, 3] . Less than 40% of patients are eligible for potential curative treatments, and systemic therapies such as standard chemotherapeutic agents are not efficacious in HCC based on randomized trials [4] [5] [6] . Hence, new therapeutic approaches are urgently needed. It is hoped that in clarifying the genomics and signaling pathways implicated in hepatocarcinogenesis, new therapeutic targets will be developed.
Personalized medicine and human cancer
HCC is a very complex tumor from a molecular perspective [7 ] . Unlike most human malignancies, HCC usually develops in the context of inflammation and organ injury. This fact, added to the number of different causes responsible for liver damage (e.g. viral hepatitis, alcohol, etc.), warrants high molecular variability and precludes any simplistic approach. For this reason, it is relevant to figure out which are the predominant molecular mechanisms for a given HCC so that their selective and effective blockade will result in the control of the disease (personalized medicine) [8] . This concept comprises the study of patients as biologic individuals, allowing customization of medical interventions according to their unique genomic background.
The complexity of the human genome is far beyond what was expected after its complete decoding in the early 2000s. New confounding factors such as alternative splicing, mRNA stability, epigenetic gene silencing, and so on, have increased the output diversity after DNA transcription. Unexpectedly, since the accomplishment of the Human Genome Project, there have not been major research breakthroughs with substantial clinical implications. Also, less than 10% of published associations between DNA alterations and disease have been validated by independent researchers [9] . These drawbacks have diminished the early enthusiastic predictions about the clinical achievements after implementation of personalized medicine. Nevertheless, certain landmark studies leave plenty of room for optimism [i.e. prophylactic surgery in women with breast cancer (BRCA)1/2 mutations [10] , selective response to tyrosine kinase inhibitors in patients with lung cancer and epidermal growth factor receptor (EGFR) amplifications [11] , etc.].
In most human malignancies, clinical classifications are essential for prognosis assessment and treatment planning. Also, they are useful to unify criteria, and to allow unbiased comparisons between groups of patients within research protocols. In the last decade, and parallel to advances in molecular oncology, genomic parameters have been progressively included in cancer classifications [12] . Unlike traditional clinical information (i.e. tumor size, presence of vascular or lymph node invasion, etc.), molecular data accounts for the biological background of the neoplasm. This is two-fold relevant; first, the type and quantity of molecular aberrations in a tumor might be surrogates of clinical aggressiveness. Several biomarkers have been proposed as prognostic and diagnostic tools in human malignancies (Table 1 [ [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] ), and they are now integrated in clinical management algorithms. Second, molecular aberrations may represent new targets for drug development. For example, human epidermal growth factor receptor (HER)2/Neu amplifications in breast cancer and EGFR overexpression/mutations in nonsmall cell lung cancer (NSCLC) identify a subgroup of patients with better response to trastuzumab and in some instances erlotinib, respectively [29, 30] . As a result, tailored therapeutic regimes based on molecular data are progressively being introduced in clinical routine (Table 2 [ 11, [31] [32] [33] [34] [35] [36] [37] [38] ). Golub et al. [39] pioneered molecular cancer classification using gene expression monitoring by DNA microarrays in acute myeloid leukemia. In this milestone study, gene expression data were able to accurately predict cancer classes, independent of previous biological knowledge of the samples. Thereafter, several studies [40] [41] [42] following the same methodology confirmed the prognostic value of gene signatures in different malignancies, including HCC. The application of molecular signatures as predictors of survival has, however, been seriously criticized. Michiels et al. [43] found a worrisome rate of misclassification in seven studies analyzed, as well as high instability in the signatures described. Thus, initial concerns related to data processing jeopardized the valuable information provided by genome-wide expression studies.
Molecular classification of hepatocellular carcinoma
Several clinical staging systems have been proposed to predict HCC prognosis but only the BCLC staging system has gained wide recognition among scientific societies [44] [45] [46] [47] . It, however, does not incorporate biological information of the tumor. Considerable efforts have been made to obtain a molecular classification of HCC (Table 3 [ 48,49 ,50-55,56 ] ), but the overwhelming genomic complexity of HCC has rendered this goal as a major challenge. Whole-genome based analysis of DNA aberrations [48, 56 ] or gene expression [53, 54] have been frequently used to define molecular subgroups. These high-throughput technologies have afforded researchers a unique opportunity to integrate a large amount of molecular information with clinical parameters. Unfortunately only two studies [48, 49 ] have comprehensively integrated data from different platforms. These multidimensional approaches complement integrative functional genomics, a term that refers to the integrated analysis of gene expression data sets from different species (human HCC, mouse models and HCC cell lines [57] ). Within this general framework, Lee et al. [54] were able to identify a new subtype of HCC patients who shared a gene expression pattern with fetal hepatoblasts [58] .
Initial studies [59 ,60] compared gene expression between HCC and nontumoral tissue, and were later improved by gene expression analysis of the whole hepatocarcinogenic process (including cirrhotic tissue and preneoplastic lesions). Ye et al. [51] studied 67 primary and metastatic HCCs by an unsupervised hierarchical clustering algorithm interrogating 9180 genes. They found that primary metastasis-free HCC had a gene expression profile markedly different from that of primary HCC with metastatic lesions, also with differences in patient survival. The 153-gene model provided a robust signature that correctly classified 100% of the training samples during cross-validation. All these data implied that genes favoring metastasis progression are initiated in the primary tumors, and authors argued that primary HCC with metastatic potential may be evolutionarily distinct from metastasis-free primary HCC. Furthermore, stringent analysis of expression data unleashed osteopontin as a relevant mediator in metastatic HCC.
Similarly, another study [61] using high-density oligonucleotide microarray reported a 12-gene signature able to predict early intrahepatic HCC recurrence with an accuracy of 93%. Subsequently, and using a different technology (adaptor-tagged competitive PCR), Kurokawa et al. [52] studied gene expression in 60 HCC patients. The authors selected a 20-gene signature out of 92 candidate genes able to predict early recurrence (<2 years). The recurrence signature (poor signature) was validated in an independent cohort of 40 patients with a predictive accuracy close to 73%. As noted, accuracy rates were lower than in previous studies, and unfortunately there were no common genes among these reports.
In 2004, Lee et al. [53] analyzed global gene expression patterns in 91 HCC to define the molecular characteristics of HCC, and to test the prognostic value of expression profiles. Unsupervised hierarchical clustering revealed two classes of HCC patients characterized by significant differences in survival (30 versus 84 months in class A and B, respectively). After supervised analysis, the authors found 406 genes whose expression was significantly informative of length of survival. Expression of typical cell proliferation markers was greater in class A. Data reported in this study did not exclude the possibility that different mechanisms were primarily responsible for two molecularly different types of tumors, referred as 'etiological footprint' by the authors. This was further explored in a second study in which they tested if global gene expression analysis of human HCC would identify subtypes of HCC derived from different cells (hepatocytes and hepatic progenitor cells [54] ). They uncovered a new subclass of HCC (hepatoblast signature) that coclustered with rat fetal hepatoblasts (Table 3 ). This signature was independently associated with both recurrence and worse survival, and it was enriched in JUN and FOS activity. The hepatoblast signature also displayed markers of hepatic progenitor cells (KRT7, KRT19 and VIM). Whether this signature is a consequence of malignant transformation of mature hepatocytes with dedifferentiation remains unclear.
Recently, Katoh et al. [56 ] proposed a molecular classification of HCC based on chromosomal alteration profiles detected with array-based comparative genomic Gene expression studies were performed on adjacent nontumoral tissue. Signatures were generated from tumoral microenvironment.
hybridization (CGH). They identified two distinct patterns (clusters A and B) after analyzing 87 HCCs. Chromosomal alterations were observed more frequently in cluster A (1q, 6p, 8q gains, and 8p losses were almost exclusive to this cluster), and patients in this cluster had worse survival. Both clusters were further subdivided in three subclasses each. Subclusters B2 and A3 harbored amplification in 17q11.2-25.3, locus of the RPS6KB1 gene, a downstream molecule of the mTOR-signaling pathway. On the basis of this finding, the authors hypothesize that patients within these subclusters could be ideal candidates for therapies using mTOR inhibitors. Likewise, patients in subcluster A1 were distinctively characterized by amplifications in 1q and/or 6p. Among several potential oncogenes in these regions, vascular endothelial growth factor (VEGF) seems to be an ideal candidate for selective target since several studies [62] [63] [64] [65] support the role of VEGF in HCC. Also, positive results of a phase III clinical trial with a tyrosine kinase inhibitor against VEGFR -sorafenib -in advanced HCC reinforce the potential role of anti-VEGFR therapy in HCC [66 ] .
The study of HCC with a systems biology approach assumes that cancer deregulates a complex network of genes and proteins. Therefore, multiparametric measurements assessing changes in this equilibrium will facilitate accurate prognostic and therapeutic modeling in a personalized medicine scenario. A pioneer study [48] following a multidimensional approach analyzed 137 HCC patients that were characterized for mutations in p53, Axin1 and b-catenin in conjunction with evaluation of allelic loss using 335 microsatellite markers. On the basis of these data, the authors were able to classify HCC patients in two groups: first, a chromosomal instability class, defined by high fractional allelic loss or gain (FAL) index (fraction of evaluable autosomal arms demonstrating allelic deletion), and frequent mutations in p53 and Axin1. This group was significantly enriched with hepatitis B virus (HBV) infection, poor differentiated tumors, and patients had worse prognosis, similarly to cluster A in Katoh's classification [56 ] . The second group, chromosomal stability, had low FAL index and mutations in b-catenin. Patients in this class tended to have larger tumors, and to be non-HBV infected. The same researchers recently reported an update of this classification expanding the parameters evaluated [49 ] . On the basis of mutations in PI3KCA, EGFR, KRAS, NRAS and HRAS, promoter methylation, gene expression evaluated with microarray, qRT-PCR and protein analysis using western blot and immunohistochemistry (IHC), they identified six groups (G1-G6, Table 3 ). G1-G3, included previously in the chromosomal instability group, were characterized by frequent allelic loss, mutations in Axin1 and p53, activation of Akt signaling and overexpression of insulin-like growth factor (IGF)-2. On the contrary, groups G5-G6 had lower rates of allelic loss (chromosomal stability), frequent b-catenin mutations and nuclear localization of b-catenin, which suggested activation of Wnt signaling. Unlike their previous report, the authors were unable to detect differences in survival within these six groups.
Recently, the Mount Sinai Liver Cancer Program performed an integrative genomic analysis on 103 hepatitis C virus (HCV)-related HCC using annotated data from single nucleotide polymorphism (SNP)-array, gene expression profiling, mutation analysis and IHC (unpublished data) [50] . Five molecular subclasses were identified after unsupervised analysis of the HCC transcriptome. Three of them further refine classes previously reported (activation of b-catenin [49 ] , proliferation [58] , and interferon-related classes). Also, this study detected a new class characterized by gains in chromosome 7.
Cellular ability to metastasize is a hallmark of cancer [67] . Few investigations addressed the contribution of host genetic background (i.e. microenvironment) in this process. Budhu et al. [55] compared the gene expression profiles of 115 nontumoral adjacent liver tissues from HCC patients with and without venous or distant metastasis. Strikingly, a signature of 17 genes generated from adjacent nontumoral tissue significantly distinguished patients with and without metastasis, with implications in patient outcome. Genes in this signature were mostly related to the immune/inflammatory response.
Remarkably, there is a certain degree of class aggregation across the different molecular classifications of HCC proposed so far. As an example, in three independent studies there is high concordance in a subclass of HCC patients characterized by dysregulation of genes related to cell proliferation (G1-G3 classes in Boyault et al.'s study [49 ] , proliferation class in Chiang et al.'s study [50] , and class A in Lee et al.'s study [54] ). Also, consistent throughout different reports, is the existence of a group of patients with recurrent chromosomal aberrations, suggesting chromosomal instability. Nevertheless, there are still contradictory data among studies, and a significant group of patients remain repeatedly unclassified.
Targeted therapies in hepatocellular carcinoma: insights from a personalized medicine approach HCC is a particular case in oncology. Unlike most of the solid tumors, deaths in HCC can be related to the tumor or to liver dysfunction. Hence, it is essential to correctly design clinical trials in HCC. To capture antineoplastic effect in an investigational drug, HCC, and not liver dysfunction, has to dictate response to treatment.
Recently, a panel of experts has published some guidelines for the design of clinical trials in HCC [68 ] .
The introduction of biological agents as therapeutic options in oncology has changed the traditional paradigm to measure the antitumoral effect of new agents in the clinical trial scenario. The most important issues are regarding which should be the primary and secondary endpoints in controlled clinical trials. Obviously, objective response is a weak surrogate of activity in phase II trials, because in most cases, the predominant effect of these compounds is basically cytostatic. In fact, bevacizumab has shown a survival benefit in patients with liver metastases, as has erlotinib in advanced lung cancer and sorafenib in renal cancer, even when objective responses were less than 10%. Therefore, it is mandatory to select primary endpoints able to capture the effects associated with stabilization of the disease for clinically relevant periods. These endpoints need to have a timeto-event format. Progression-free survival is the best endpoint in most human malignancies, but it is not appropriate in HCC as it combines two types of events: progression and death due to any cause. Therefore, it is recommended the inclusion of time-to-progression (period between the inclusion in the study and the radiological progression of the disease) as the primary endpoint in phase II trials, and survival as the endpoint in phase III trials [68 ] .
Several studies have tried to establish the activation status of different signaling pathways in HCC. Data suggest activation of numerous oncogenic signaling routes in HCC (i.e. epidermal growth factor (EGF), IGF and HGF signaling, RAS/mitogen-activated protein kinase (MAPK), Akt/mTOR pathway, NF-kb, TGF-b signaling, Wnt-b catenin, etc. [7 ,69] ). Consequently, several drugs have been developed to block these pathways at different levels (Fig. 1) . Nevertheless, as pathway activation is not uniform in all HCC patients, it would be desirable to know a priori which pathway is activated in every patient. This concept is tightly linked to the molecular classification of HCC as some molecular classes are led by the activation of certain pathways (e.g. b-catenin in class G5-6 of Boyault et al. [49 ] ).
Different phase II and III trials have evaluated molecular therapies in HCC [38,66 ,70-75] . Most of them used drugs that block EGF signaling (erlotinib) and angiogenesis (bevacizumab), and there is only one study that analyzed association regimes with traditional chemotherapy [74] . Eckel et al. [70] reported a phase II trial testing imatinib in 17 HCC patients. The authors reported a median survival of 12 weeks and 33% of patients with stable disease. Interestingly, only one of the patients in this trial had a tumor positive for plateletderived growth factor receptor (PDGFR) and none were positive for c-Kit. It is difficult to know if imatinib could play a role in HCC if almost none of the patients in this trial had activation of two of the most relevant targets of this drug. Two phase II trials have been conducted with erlotinib in HCC [72, 73] . Both studies analyzed EGFR receptor status with IHC, and both agreed in the absence of predictive power of this marker for response to erlotinib. On the contrary, significant differences were reported in time-to-progression in patients treated with sorafenib according to the phosphorylation status of extracellular signal-regulated kinase (ERK), a known downstream molecule of B-RAF (Table 2 ) [38] . It is unclear if the selection of IHC for total EGFR as biomarker of response to erlotinib is accurate enough in HCC. In other malignancies, the presence of amplifications or phosphorylation of EGFR (hallmark of activation of the receptor), and other downstream molecules predicted response to tyrosine kinase inhibitors [76] .
A major breakthrough occurred in 2007 in the targeted therapy field in HCC. An oral multikinase inhibitor (sorafenib) with activity against several tyrosine kinases (VEGFR2, PDGFR, c-Kit receptors), and serine/ threonine kinases (B-RAF, p38) was able to significantly increase survival in patients with advanced HCC [66 ,77] . This was the first phase III trial to show positive results with a target therapy in HCC, and it was also the first systemic therapy to increase survival in advanced HCC. The randomized phase III double-blind placebocontrolled clinical trial conducted in patients with advanced HCC treated with sorafenib has shown improvement in survival of 3 months in patients with advanced HCC, which was not only statistically significant but also clinically meaningful [66 ] . The study was stopped at the second planned interim analysis because of survival advantages favoring the treatment arm. The median overall survival was 10.7 months with sorafenib and 7.9 months with placebo (hazard ratio for death, 0.69; 95% confidence interval, 0.55-0.87; P < 0.001). The magnitude of the difference, reflected by the hazard ratio of 0.69, compares well with the differences obtained with other targeted therapies in colorectal (cetuximab, bevacizumab), renal (temsirolimus), breast (trastuzumab), and lung cancer (erlotinib). Median time to progression was 5.5 months with sorafenib versus 2.8 months with placebo (hazard ratio 0.58; 95% confidence interval 0.45-0.74; P < 0.001). Seven patients (2.3%) in the sorafenib group and two patients (0.7%) in the placebo group achieved a partial response. Recently, the drug has been approved both by Food and Drug Administration (FDA) and European Medicines Agency (EMEA) for the treatment of HCC.
Sorafenib targets two of the main pathways involved in hepatocarcinogenesis by blocking angiogenesis (VEFGR2 and PDGFR) and cell proliferation through Ras/MAPK signaling (b-RAF). An exhaustive analysis of the trial data suggests that the majority of patients receiving sorafenib achieve some clinical benefit. It is biologically plausible that a drug able to block different molecules will benefit a wide range of patients as many signaling pathways will be targeted simultaneously. Thus, sorafenib is de facto acting as a multitarget therapy in HCC. Additional challenges will be to combine this drug with other targeted therapies blocking signaling networks untouched by sorafenib, particularly in those patients with chromosomal instability that could have several signaling pathways aberrantly activated. Potential combination therapies are summarized in Fig. 1 .
Conclusion
The development of a molecular classification of HCC is crucial. Until the molecular pathogenesis of HCC is completely understood, it would be complicated to achieve high rates of treatment success with targeted therapies. Many progresses have been made in this regard, and preliminary reports using genome-wide approaches confirm the high genetic heterogeneity of HCC. It seems that a subgroup of patients have activation of pathways related to cell proliferation (IGF signaling, RAS/MAPK and mTOR signaling), and differentiation (Wnt-b-catenin and Hedgehog). Cause of the underlying liver disease also seems to confer specific chromosomal aberrations. It is also clear that tumor microenvironment plays a major role in HCC intrahepatic metastasis. Probably, gene expression studies will soon allow predicting risk for HCC development based on the gene signature in cirrhotic tissue. Fortunately, sorafenib has opened the trail for target therapies in HCC.
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Figure 1 Signaling pathways and targeted therapies in hepatocellular carcinoma
This figure summarizes some of the most relevant signaling pathways analyzed in human HCC (RAS/MAPK, Akt/mTOR, Wnt-b-catenin and Hedgehog). Also, it shows different drugs in clinical and preclinical development for the specific blockade of these pathways. BAD, Bcl2-antagonist of cell death; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; ERK, extracellular-signal regulated kinase; FDA, Food and Drug Administration; IGF, insulin-like growth factor; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase; PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor receptor; PTC, patched homolog 1; RAF, murine leukemia viral oncogene homolog 1; RAS, rat sarcoma viral oncogene 1; VEGF, vascular endothelial growth factor.
Certainly, the conjunction of precise knowledge of the molecular classes of HCC, well designed clinical trials, and effective blockade of specific pathways with new therapies will definitely implement personalized medicine for the clinical management of HCC.
